For the most up to date information on COVID-19 please visit the Department of Health website. Learn more about how the AIHW is assisting the COVID-19 response and how our other work is affected. Our Covid-19 related resources page includes a list of some existing resources which may be useful when researching issues related to COVID-19.
Australian Institute of Health and Welfare 2020. National Opioid Pharmacotherapy Statistics Annual Data collection 2019. Cat. no. PHE 266. Canberra: AIHW. Viewed 25 September 2020, https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/national-opioid-pharmacotherapy-statistics-2019
Australian Institute of Health and Welfare. (2020). National Opioid Pharmacotherapy Statistics Annual Data collection 2019. Retrieved from https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/national-opioid-pharmacotherapy-statistics-2019
National Opioid Pharmacotherapy Statistics Annual Data collection 2019. Australian Institute of Health and Welfare, 31 March 2020, https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/national-opioid-pharmacotherapy-statistics-2019
Australian Institute of Health and Welfare. National Opioid Pharmacotherapy Statistics Annual Data collection 2019 [Internet]. Canberra: Australian Institute of Health and Welfare, 2020 [cited 2020 Sep. 25]. Available from: https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/national-opioid-pharmacotherapy-statistics-2019
Australian Institute of Health and Welfare (AIHW) 2020, National Opioid Pharmacotherapy Statistics Annual Data collection 2019, viewed 25 September 2020, https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/national-opioid-pharmacotherapy-statistics-2019
Get citations as an Endnote file:
PDF | 702Kb
On a snapshot day in 2019, over 50,000 clients received pharmacotherapy treatment for their opioid dependence at 2,940 dosing points across Australia. There were 3,395 authorised prescribers of opioid pharmacotherapy drugs.
2 in 3 opioid pharmacotherapy clients were male
Around 1 in 10 opioid pharmacotherapy clients identified as being Aboriginal and/or Torres Strait Islander
50,945 clients received opioid pharmacotherapy treatment nationally
There were 2,940 opioid pharmacotherapy dosing points
Dependence on opioid drugs is associated with a range of health and social problems that affect individual drug users, their family and friends, and the wider public.
Opioids are chemical substances that have a morphine-type action in the body. They are most commonly used for pain relief, but they are addictive and can lead to drug dependence. They include:
Opioid drugs can be:
Since 1 February 2018, access to all medicines containing codeine has required a prescription.
Drug dependence is characterised by drug seeking and using, but people experience it in various ways. The International statistical classification of diseases and related health problems, 10th revision (ICD-10) (WHO 2010) defines 'dependence syndrome' due to the use of opioids as:
'A cluster of behavioural, cognitive, and physiological phenomena that develop after repeated substance use and that typically include a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal state (Code F11.2).'
Opioid drug use and dependence is associated with a range of health and social problems including:
Opioid pharmacotherapy treatment is one of the main treatment types used for opioid drug dependence and involves replacing the opioid drug of dependence with a legally obtained, longer-lasting opioid that is usually taken orally.
Opioid pharmacotherapy treatments (such as methadone or buprenorphine) can:
In Australia, 3 medications are registered for long-term maintenance treatment for opioid-dependent people:
Opioid pharmacotherapy treatment is administered according to the law of the relevant state or territory, and within a framework that includes medical, social and psychological treatment. The Australian Government Department of Health, as part of the National Drug Strategy, published the National Guidelines for Medication-Assisted Treatment of Opioid Dependence (DoH 2014) to provide a broad policy context and framework for state and territory policies and guidelines that are concerned with the medication-assisted treatment of opioid dependence.
The National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) collection is compiled from jurisdictional data and provides information about:
Data are reported on a snapshot day in June each year. The snapshot day varies across jurisdictions. This is because each state and territory uses a slightly different method to collect data. These are driven by jurisdictional differences, such as legislation, computer systems and resources. These differences may result in minor discrepancies when comparing one jurisdiction to another.
National Opioid Pharmacotherapy Statistics Annual Data collection data quality statement.
DoH (Department of Health) 2014. National guidelines for medication-assisted treatment of opioid dependence. Canberra: DoH for National Drug Strategy. Viewed 23 December 2019.
NSW Clinical Guidelines: Treatment of Opioid Dependence – 2018. PDF Download viewed 23 December 2019.
Ritter A & Chalmers J 2009. Polygon: the many sides to the Australian opioid pharmacotherapy maintenance system. ANCD research paper no. 18. Canberra: Australian National Council on Drugs.
Roxburgh A, Bruno R, Larance B & Burns L 2011. Prescription of opioid analgesics and related harms in Australia. Medical Journal of Australia 195:280–284.
WHO (World Health Organization) 2010. Mental and behavioural disorder due to the use of opioids: dependence syndrome. ICD-10: International statistical classification of diseases and related health problems. Viewed 23 December 2019.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.